# A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

> **NCT06521554** · PHASE1 · RECRUITING · sponsor: **Nuvalent Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Locally Advanced Solid Tumor
- Metastatic Solid Tumor

## Interventions

- **DRUG:** NVL-330

## Key facts

- **NCT ID:** NCT06521554
- **Lead sponsor:** Nuvalent Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-18
- **Primary completion:** 2027-01
- **Final completion:** 2027-02
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06521554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06521554, "A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06521554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*